G protein-coupled receptors (GPCRs) are the largest family of membrane receptors and targets for approved drugs.
magnitude of GPCR expression. We also provide independent qPCR validation of GPCR expression data from TaqMan arrays and RNA-seq and evidence for the predictive value of data from the latter techniques in terms of signaling and physiological response of Gq/11-coupled GPCRs.
Here, we assess GPCR expression data for the following human cells and tissues: 1) pancreatic CAFs (using Affymetrix HG U133plus2.0 arrays, Taqman arrays and RNA-seq); 2) cardiac fibroblasts (CFs), pulmonary arterial smooth muscle cells (PASMCs) and pancreatic stellate cells (PSCs) (using Taqman arrays and RNA-seq); 3) APSC-1 pancreatic cancer cell line (from CCLE, via Affymetrix HG U133plus2.0 plus RNA-seq and via Taqman arrays in our laboratory); 4) MDA-MB-231 breast cancer cell line (from CCLE via Affymetrix HG U133plus2.0 and RNA-seq); 5) Ovarian cancer (OV) tissue and Lung Squamous Cell Carcinoma (LUSC) tissue (from TCGA, via Affymetrix HGU133a and RNA-seq). This large number of sample types (also listed in Table S1), with data collected from different sources, facilitated a robust comparison of GPCR detection and revealed prominent differences in data generated by the different methods. These findings provide insights regarding GPCR expression by various cell types, a rationale for interpretation of mined data regarding GPCR expression, and evidence for the utility of mRNA expression data in predicting functional activity of one class of GPCRs (Gq/11-coupled GPCRs). Together such information should aid studies of GPCR biology and drug discovery.
Methods
Cell Culture and RNA isolation CAFs were isolated from primary human PDAC tumors via explant and were grown as described previously 3 . At low passage (<5), CAFs were plated in 10 cm plates and grown in 5% CO2 at 37°C. Cells were lysed and RNA was isolated using a Qiagen RNeasy kit (Cat # 74104, Qiagen, Hilden, Germany), with on-column DNase-1 digestion (79254, Qiagen). Purified RNA had 260/280 ratios ~2 (via Nanodrop 2000c, ThermoFischer Scientific, Waltham, MA) and RNA integrity number (RIN) scores >9 (via Bioanalyzer, Agilent Technologies, Santa Clara, CA). Human fetal cardiac fibroblasts (CFs) were obtained from Cell Biologics, Cat # H6049 (Chicago, IL) and grown in 10% CO2 at 37°C, in low-glucose DMEM (Cat # D60646 Gibco, Dublin, Ireland) with 2% FBS (Cat # FB-02, Omega Scientific Inc, Tarzana, CA), 5 μg/L FGF2 (Cat # 130093838, Miltenyi Biotec, San Diego, CA), 5 mg/L insulin (Cat # SC360248, Santa Cruz Biotechnology, Dallas, TX), 1 mg/L hydrocortisone hemisuccinate (Cat # 07904, Stemcell Technologies Inc, Cambridge, MA) and 50 mg/L ascorbic acid (Cat # A454425G, Sigma Aldrich, St Louis, MO).
Pulmonary arterial smooth muscle cells (PASMCs) were obtained from Lonza (Cat # CC-2581, Walkersville, MD) and were cultured in 5% CO2 at 37°C in low glucose DMEM with 5% FBS, EGF (5 ng/mL), FGF2 (5 ng/mL, Cat # 130093837, Miltenyi Biotec), insulin (same as above) and ascorbic acid (50 μg/mL). Pancreatic stellate cells (PSCs) were purchased from ScienCell Research Laboratories (Cat # 3830; ScienCell Research Laboratories, Carlsbad, CA) and cultured according to the manufacturers' instructions.
qPCR:
RNAs were converted to cDNA via the Superscript III kit (Cat # 18080050, Thermo Fisher Scientific, Waltham, MA).
cDNA was then mixed with gene-specific primers (2 μM) and Perfecta SYBR green SuperMix reagent (Cat # MP9505402K, VWR, Radnor, PA) for PCR amplification using a DNA Engine Opticon 2 system (MJ Research, St.
Bruno, QC, Canada). Primers were designed using Primer3Plus software. The primer sequences are listed in Supplemental Table S3 .
RNA-seq:
RNA sequencing was performed by DNAlink Inc (San Diego, CA for CAF samples) or the UCSD IGM core (for CF and PASMC samples), using Truseq (Illumina, San Diego, CA) stranded mRNA library preparation, with sequencing on a Nextera 500 (for CAF samples) or a Hiseq4000 (CF and PASMC samples) at 50 (CFs and PASMCs) or 75 (CAFs) base pair single reads. Data were analyzed via Kallisto v0.43.1 4 using the Ensembl GRCh38 v79 reference transcriptome, with 100 bootstraps, to obtain transcript-level expression in transcripts per million (TPM). Kallisto bootstraps were read in R via Sleuth; 5 GPCR data for each bootstrap were evaluated as described below to quantify uncertainty of GPCR expression quantification. Gene-level expression in TPM) was calculated using Tximpor 6 For comparison of expression ratios of gene expression between samples, gene-level estimated counts data from tximport were input into edgeR, 7 to obtain normalized gene expression in counts per million (CPM). RNA-seq raw data are available at NCBI GEO, at accession numbers GSE101665 and GSE125049. 8 ; based on previous studies, we set the TaqMan GPCR array detection threshold to a ∆Ct value (relative to 18S) ≤ 25. 3, 8, 9 Affymetrix arrays:
RNA samples were submitted to the Technology Center for Genomics & Bioinformatics (TCGB) at UCLA for analysis via Affymetrix HG U133plus2.0 arrays. Data as cel files were analyzed by both the MAS5 and RMA methods to quantify gene expression. Analysis was performed via the R 'affy' package 10 to yield intensity estimates for each probe-set, along with detection p-values and present/absent calls (for the MAS5 method). For a GPCR to be considered 'detected' in Results, the Mas5 call was required to indicate 'P' (present) for at least one probe set for a given gene. In the event that multiple different probesets for the same GPCR indicated a 'P' call (with corresponding p-values < 0.05), we used the expression from the probe-set indicating highest MAS5 expression intensity, which yielded expression-ratio estimates between replicates consistent with RNA-seq and qPCR, as detailed further in Results. In general, Log2 Mas5 intensities >5 correspond to 'present' calls (see Figure S3 and accompanying text on dynamic range for further details). Affymetrix data are available at NCBI GEO, at accession number GSE124945.
Data mining:
TCGA data for ovarian cancer (OV) and Lung Squamous Cell Carcinoma (LUSC) assayed by RNA-seq were downloaded from xena.ucsc.edu, as estimated gene counts and TPMs for each gene in each TCGA sample, analyzed via the TOIL pipeline. 11 TCGA data for OV and LUSC, assayed by Affymetrix HG U133a arrays, were obtained from GEO (accession numbers GSE68661 and GSE68793 for OV and LUSC respectively) and were analyzed in R, using the methods described above for Affymetrix arrays. For computation of expression ratios between samples, estimated counts from the TOIL pipeline were input into edgeR, to obtain normalized gene expression in CPMs, allowing for comparison of expression ratios for genes between pairs of samples. RNA-seq data from the CCLE 2 for cell lines were downloaded as gene expression in TPMs from the EBI expression atlas, 12 from data provided on that portal, analyzed via the iRAP pipeline. 13 Cellular calcium assays:
Intracellular calcium concentration of AsPC-1 cells was measured using the FLIPR-4 calcium assay reagent (Cat # R8142, Molecular Devices, San Jose, CA). In brief, cells were plated in black-walled clear-bottom 96-well plates overnight at ~80% confluency using media and conditions described above. Culture media was then removed and cells were incubated for 1 h at 37 °C, 5% CO2 in FLIPR-4 loading buffer, consisting of FLIPR-4 reagent diluted (as per the manufacturer's instructions) in HBSS (with calcium and magnesium) buffered with 20 mM HEPES and 0.2% BSA, with pH adjusted to 7.4. Loading buffer also contained probenecid (2.50 mM, Sigma Aldrich, Cat # P8761), to prevent leakage of the calcium reagent from the cells. Calcium response was then measured via a FlexStation 3
Multi-Mode Microplate Reader (Molecular Devices). GPCR agonists were added and response in RFU (Relative Fluorescence Units) was measured over 105s for each well, yielding data for peak response and kinetics of response. For calcium assays and wound healing assays, we used the following GPCR agonists: Neurotensin (Cat # 1909, Tocris, Minneapolis, MN); 2-Thio-UTP (Cat # 3280, Tocris); Histamine (Cat # AAJ6172703, Fischer Scientific); Oxytocin (Cat # 1910, Tocris) and Sulprostone (Cat # 14765, Cayman Chemical).
Migration/wound healing assays:
Rate of migration of AsPC-1 cells was estimated using a scratch-wound assay. Cells were plated in 24-well plates and grown to approximate confluency. A scratch was made in each well using a 200 μL pipette tip, culture media was replaced to remove floating cells and the scratches were imaged using a BZ-X700 microscope. Cells were then incubated with GPCR agonists at concentrations described in the following sections and were returned to a 37 °C, 5% CO2 incubator. 24h later the same scratches were imaged once again. The area of scratches at the 0 and 24h time points was then calculated via standard protocols in ImageJ v1.52a to evaluate wound closure. Migration data were analyzed for statistical significance using Prism Graphpad (GraphPad Software, San Diego, CA) via one-way ANOVA with Tukey multiple comparison testing.
Results

Figure 1. Detection of GPCRs by RNA-seq, Taqman GPCR arrays and Affymetrix (Affy) arrays. a-c)
GPCRs for which the relevant primer probes are present by each method. Representative data are shown for an individual CAF replicate as an example; similar numbers were detected by all three methods in a second replicate. d) Differences in GPCR expression between RNA-seq and Taqman arrays. e) False positive detection of GPCRs from Affymetrix HG U133plus2.0 arrays; these GPCRs were detected by neither RNA-seq (plotted above) nor Taqman arrays (not shown) (f) False negatives from Affymetrix arrays that we detected by the other methods; expression is plotted for such GPCRs identified by RNA-seq
Comparison of GPCR expression data for pancreatic CAFs
Table S2 (top) shows the number of GPCRs each method can detect, based on limitations of the number of primers (TaqMan arrays) or probes (Affymetrix arrays). Both methods should allow detection of a similar number of endoGPCRs. TaqMan arrays are not designed to detect chemosensory GPCRs and Affymetrix arrays also have relatively few probe-sets for chemosensory GPCRs. Figure 1 and Table S2 (bottom) show that the number of endoGPCRs in pancreatic CAFs detected by RNA-seq and TaqMan arrays is greater than is detected by Affymetrix arrays. The threshold of detection used for determining whether a GPCR was detected in RNA-seq data was set to 0.2 TPM, based on analysis discussed in Figure S1 and accompanying text. Detection thresholds for TaqMan arrays and Affymetrix arrays are discussed in Methods.
RNA-seq identified the greatest number of GPCRs, likely because this method is not limited by a fixed number of probes/primers. RNA-seq and Affymetrix HG U133plus2.0 arrays both detect a small number of chemosensory GPCRs; their level of expression was typically just above the detection thresholds defined above and in Methods.
Both RNA-seq and TaqMan arrays identified in common most of the detected GPCRs. Virtually all highly expressed GPCR identified by either Taqman arrays or RNA-seq were commonly detected by both, whereas Affymetrix arrays detected fewer GPCRs in common (Figure 1 a-c) . GPCRs uniquely identified by each method were typically expressed at very low levels, i.e., near detection thresholds. Eight endoGPCRs were detected by RNA-seq but not by TaqMan arrays due to the absence of corresponding primers on the Taqman arrays.
The overall agreement between Taqman arrays and RNA-seq is further illustrated in Figure 1 d-f : the 21 GPCRs detected by TaqMan arrays but that were below thresholds for detection by RNA-seq were all expressed at >22 Cycles above 18S (i.e. > ~33 qPCR cycles), implying low expression levels of these receptors by either method (Figure 1d) . Thus, all highly expressed GPCRs identified by TaqMan arrays are also detected by RNA-seq. We Independent qPCR using SYBR green and primers designed in our lab was used to validate GPCR expression measured by the 3 methods. Figure 2c shows the average expression of 10 GPCRs in CAFs derived from 5 different patients, assayed via independent qPCR and the correspondence of these data with Taqman array data.
We found a high degree of correspondence with results from TaqMan arrays and qPCR (R 2 was observed for n replicates tested by the Affymetrix arrays. Fewer GPCRs are consistently detectable by Affymetrix HG U133plus2.0 arrays; estimation of changes in GPCR expression is thus less feasible than with the other methods. However, for GPCRs that one can consistently quantify by Affymetrix arrays, estimates of differences in their expression are consistent with those of the other two methods. Figure S3 (and accompanying text) shows quantitative analysis for the dynamic range of detection of GPCRs by each method, from data in CAFs.
Affymetrix arrays have a narrower dynamic range than TaqMan arrays or RNA-seq, which both show very similar behavior. In addition, the correlation for all genes in general, between RNA-seq and Affymetrix arrays appears poor. We obtained a similarly high degree of correspondence between TaqMan array and RNA-seq data in other cell types. Figure 3 a-c shows the detection of GPCRs by TaqMan arrays and RNA-seq in human cardiac fibroblasts, pancreatic stellate cells (PSCs) and pulmonary arterial smooth muscle cells (PASMCs). Most GPCRs are identified by these two methods in all 3 cell types. Similar to the data from CAFs, the GPCRs commonly detected by both Taqman arrays and RNA-seq include all highly expressed GPCRs (e.g. those expressed >10 TPM). Thus, GPCR expression analysis by TaqMan arrays and RNA-seq is consistent in a variety of primary cell types.
Comparison of GPCR expression estimates in other cell types
To further test Affymetrix arrays with the two other methods, we assessed expression of GPCRs in AsPC-1 PDAC cells using TaqMan arrays and compared these data with RNA-seq and Affymetrix HG U133plus2.0 array data for the same GPCRs from data in CCLE 2 . We found that our TaqMan array data and the CCLE RNA-seq data showed much better correspondence than did the CCLE Affymetrix data to either of those methods/sources (Figure 3 d-f) .
Thus, GPCR expression determined by RNA-seq and TaqMan arrays assayed at different laboratories, batches of cell lines, media etc. shows greater concordance than GPCR data from RNA-seq and Affymetrix arrays, for samples prepared in the same laboratory.
We also assessed data for another cell line (MDA-MB-231 breast cancer cells) from CCLE and for tumor tissue from TCGA. We compared data from CCLE using Affymetrix HG U133plus2.0 arrays and found a similarly poor correlation between GPCR expression assayed by the Affymetrix arrays compared to RNA-seq (Figure 3 d-e ).
Fewer GPCRs were detected by the Affymetrix arrays than by RNA-seq and the magnitudes of GPCR expression were poorly correlated (R 2 = 0.58). Figure 3f shows the expression in AsPC-1 cells (from CCLE data) of 5 Gq/11coupled GPCRs determined by RNA-seq and Affymetrix arrays; these GPCRs were subsequently studied for their functional effects ( Figure 5 ). RNA-seq reveals a range of expression levels between these GPCRs, with NTSR1 and P2RY2 very high expressed while the other highlighted receptors had lower expression. By contrast, data from Affymetrix arrays implied a similar, very high level of expression for four of these GPCRs. Consistent with the RNAseq data, data from TaqMan arrays also showed that NTSR1 and P2RY2 are especially high expressed in AsPC-1 pancreatic cancer cells (not shown), while the other receptors had lower expression.
Comparison of GPCR expression estimates in tumor tissue
We next tested how well RNA-seq and the Affymetrix arrays compare in assessment of GPCR expression in human tissues and in the ratios of GPCR expression in pairs of samples. For this comparison, we used gene expression data from The Cancer Genome Atlas (TCGA) for Lung squamous cell carcinoma (LUSC) and Ovarian cancer (OV) tumors. As we observed for cells, the two methods compare poorly in terms of number of GPCRs detected and magnitude of expression of individual GPCRs in the tissue samples. Figure 4 a-d shows the relationship between RNA-seq and Affymetrix HG U133a array data from the same tumor/donors for representative LUSC and OV samples with poor correspondence for data by the two methods (R 2 =0.19 for LUSC and R 2 =0.26 for OV). RNAseq identified many more GPCRs but even for GPCRs detected by both methods, there was a poor correlation in the magnitudes of expression between the methods. The HG U133a arrays are an older, less comprehensive (i.e., smaller number of probes) product than the HG U133plus2.0 arrays we tested with CAF samples but large amounts of archived gene expression data use these or older arrays. Such archived data should thus likely be avoided for evaluating GPCR expression.
Assessment of GPCR expression between random pairs of tumor sample replicates reveals relatively poor ability
to detect GPCR expression by Affymetrix HG U133a arrays compared to RNA-seq (Figure 4 e-f ). The ratios of expression also do not correlate between the two methods, thus providing further evidence that data from older generations of Affymetrix arrays are unlikely to yield accurate data regarding GPCR expression. 
RNA-seq data suggest splice variation occurs among GPCRs
An additional advantage of the use of RNA-seq to assess GPCR expression is its ability to identify alternatively spliced transcripts, a largely unexplored aspect for GPCRs. Approximately 45-50% of GPCRs are intron-less, which may explain why splice variation in GPCRs has not been studied in detail. 14, 15 We found that many GPCRs, in particular adhesion GPCRs, which have a large number of exons, may undergo alternate splicing. Figure S2a shows the number of GPCRs and those that express multiple splice variant in a human pancreatic CAF sample.
Nearly half of all identified GPCRs appear to show alternative splicing. As an example, ADGRE5/CD97, an adhesion GPCR, appears to have at least 5 meaningfully expressed splice variants (Figure S2b) . These data were obtained at moderate sequencing depth; in order to more precisely identify the presence of particular splice variants in individual samples and cell types, one requires greater sequencing depth (e.g., sequencing with 150 base-pair, paired-end reads). Subsequent studies would then be needed to define biological activity of such variants. Of the three methods used here, only RNA-seq can define alternative splicing of GPCRs and with bioinformatics tools (such as Kallisto 4 ) can quantify transcript levels. Figure S2c shows the number of detected variants for each GPCR where we noted evidence for splice variation. To validate the GPCR expression data, we tested whether the level of mRNA expression can predict GPCR response with respect to signaling and functional activities. We opted to study a set of GPCRs which couple to Gq/11 Gα proteins, thus signaling via increases in intracellular calcium: NTSR1 (the Neurotensin receptor), P2RY2
GPCR mRNA expression shows concordance with signaling and functional response
(the P2Y2 purinergic GPCR), HRH1 (the Histamine H1 receptor), OXTR (the Oxytocin receptor) and PTGER1 (the EP1 prostaglandin receptor), spanning a range of expression (assayed via RNA-seq in CCLE 2 ) from >100 TPM (NTSR1) to 1 TPM (PTGER1) in AsPC-1 pancreatic cancer cells (Figure 5A) . All 5 GPCRs have well-known agonists that act via Gq/11 25 : Neurotensin (NTSR1); 2-Thio-UTP (P2RY2), Histamine (HRH1), Oxytocin (OXTR) and sulprostone ( PTGER1). Each agonist should activate the specified receptor due to their known pharmacology and based on the GPCRs expressed in AsPC-1 cells. For example, HRH1 is the only HRH receptor, OXTR is the only vasopressin and oxytocin receptor family member expressed and among targets for sulprostone, PTGER1 is the only one expressed in AsPC-1 cells. Similarly, P2RY2 is the only purinergic GPCR expressed, which is activated by 2-Thio-UTP.
We first tested the calcium response (i.e., the increase in cytosolic calcium) in AsPC-1 cells for each agonist, over a range of concentrations. Figure 5a shows the peak ("maximal") calcium signal recorded for each ligand (at saturating concentrations [Figure 5b] ) as a function of the magnitude of expression of its cognate GPCR target.
We observed a sigmoidal behavior, wherein the calcium response plateaus for highly expressed GPCRs; the maximal signal was equal to that elicited by ionomycin, a positive control. PTGER1 did not elicit a signal, implying that 1 TPM may be a threshold for detection of Gq/11 signaling in these cells by this method. Figure 5b shows the concentration-response for each agonist that increases cytosolic calcium. The apparent EC50 values for these ligands vary somewhat from values in the literature, for example, the EC50 for neurotensin signaling at NTSR1 is ~ 0.3 nM, approximately an order of magnitude lower than that reported in the literature 25 . This raises the possibility that signaling in native cells may differ from that in model systems where such data are typically generated. The kinetics for ionomycin and for agonists at concentrations approximately corresponding to half-maximal response (Figure 5c) suggest differences in the rates of activation of the different GPCRs, although the calcium transient is ~ 60-90s in all cases.
We next tested the ability of these agonists (excluding sulprostone, as we obtained no evidence of calcium response for this compound), to stimulate migration (using a wound-healing assay) at concentrations that correspond to maximal activation of their respective GPCRs. Figure 5d shows the effect of agonist treatment on the rate of woundclosure, compared with vehicle-treated cells. We used cells plated without serum as a negative control. Higher GPCR expression and stronger calcium response results in greater stimulation of migration (Figure 5e and f) , thus allowing us to relate GPCR expression, signaling and functional response. Based on data in Figure 3f , Affymetrix data in the same cell line, from the same source (CCLE) failed to resolve the differences in expression between these GPCRs that were observed via RNA-seq. As a consequence, the data from the Affymetrix arrays did not permit accurate identification and stratification of GPCRs based on their expression and hence those results could not reliably predict which GPCRs were highly enough expressed to yield a strong functional response. Thus, data from Affymetrix arrays do not reliably identify the GPCRs that are most highly expressed. In screening for expression of GPCRs for subsequent drug/target discovery studies, Affymetrix arrays should likely be avoided in favor of other methods.
Discussion
Comparison of three methods for high content screening of GPCR mRNA expression reveals that TaqMan GPCR arrays and RNA-seq show comparable performance, whereas Affymetrix arrays perform at a lower level. A likely reason for the latter result is the generally low expression of GPCRs, such that they are outside the dynamic range for optimal detection by arrays designed to assess the entire transcriptome. Highly expressed GPCRs, especially ones that are well-characterized, are generally reliably detected by either TaqMan GPCR arrays or RNA-seq. By contrast, Affymetrix arrays fail to identify large numbers of GPCRs and show poor correlation of expression and estimates for changes in expression compared to the other two methods. GPCRs, as a large family of genes, with a large (3 orders of magnitude) range of expression provide additional support for the accuracy and completeness, especially of RNA-seq data, and complement other validation studies. 16 The numerous false negatives observed with Affymetrix data are likely attributable to lower sensitivity, i.e., for expression thresholds < 4-5 TPM in corresponding RNA-seq data, GPCRs will frequently be undetected by Affymetrix arrays.
Comparison of the three methods ( Table 1) shows that TaqMan arrays or RNA-seq are preferable for GPCR detection and profiling. TaqMan arrays require minimal bioinformatic effort and thus can rapidly generate data.
Important advantages of RNA-seq include: 1) the number of GPCRs that are potentially detectable (Table S2) , since gene-specific primers or probes are not needed and 2) RNA-seq detects non-GPCR genes (including data for post-GPCR signaling components), yielding far more information than do TaqMan arrays. RNA-seq thus has the potential to explore other aspects of GPCR biology, such as pathways for cellular regulation.
As a consequence of the ongoing decrease in cost of sequencing, the potentially lower expense to conduct RNAseq is another advantage of this technique. A "hidden" cost of RNA-seq involves data analysis and storage, which can substantially increase the expenditure for RNA-seq. RNA-seq requires time for library preparation and sequencing, as well as bioinformatic analysis. By contrast, data analysis of qPCR-based arrays can be done quickly.
Other qPCR-based arrays are available that may yield comparable data but at a lower cost than TaqMan® arrays, e.g., SYBR green-based arrays (e.g. Cat # 10034500 [Bio-Rad] and Cat # PAHS-071Z [Qiagen]).
A further advantage of RNA-seq is that it has become a method of choice for many large databases and consortia (e.g., TCGA and GTEx 17 ). The abundance of such publicly available RNA-seq data facilitates data mining and yields information for new studies, including with respect to GPCR signaling components and how GPCRs and such components may have altered expression profiles during physiologic perturbations and in disease states. Limited public data are available for GPCR arrays so mining of such data is less feasible.
Affymetrix array-derived data is found in sources such as Gene Expression Omnibus (GEO) and other databases and for many years has been used for data mining. The findings here suggest that for GPCRs, mining of Affymetrix array data is not advisable. Moreover, to the extent that GPCRs may be differentially expressed in cells or tissues, such as in disease, 3 the large number of false negative results from Affymetrix arrays may impact on other analyses, such as in pathways and networks, in which GPCRs may be involved. The inferior dynamic range of Affymetrix arrays is likely not limited to GPCRs and may impact on the detection of other low expressed, but functionally important, genes. Thus, caution is advised in the use of Affymetrix arrays and mining of Affymetrix array data.
The study of the 'GPCRome' and individual GPCRs identified by the methods compared here has the potential to yield important insights regarding the regulation of cells and tissues in health and disease. Moreover, GPCRs are targeted by ~35% of FDA-and EMA-approved drugs 1 and represent the largest family of drug targets. Given their high druggability, identification of GPCRs in novel contexts can aid in drug discovery efforts. 18 The current results and other data show that cells express large numbers of (>100) GPCRs; these include GPCRs targeted by approved drugs, orphan receptors and many GPCRs for which tool compounds (but not approved drugs) may exist. Multiple studies of 'GPCRomics' combined with signaling and functional analyses have revealed novel roles for GPCRs in numerous cell types. 3, 8, [19] [20] [21] [22] A growing number of studies have also begun to reveal the extent to which the presence of splice variants among GPCRs may impact their functional activity. 14, 15 Consequences of such alternative splicing include the presence of receptor isoforms with altered ligand binding (primarily due to changes in the N-terminus), altered downstream signaling (including 'decoy' receptors that bind ligands but have no functional activity), and potential effects on receptor trafficking, internalization and localization within specific cellular domains. This remains a largely understudied aspect of GPCR biology. The presence of numerous GPCR splice variants at the mRNA level underscores the need for further investigation.
Because mRNA expression may not necessarily predict protein expression, we undertook functional studies of Gq-coupled GPCRs to test the concordance of mRNA expression with signaling/functional data. In general, for GPCRs, direct measurement of protein expression has been challenging, due to a) difficulty in obtaining wellvalidated antibodies and b) the low magnitude of expression of GPCRs. Thus, indirect methods to verify protein expression are needed. Here, we show that GPCR mRNA expression predicts signaling and functional response for multiple Gq/11-coupled GPCRs in a pancreatic cancer cell line. Highly expressed GPCRs (e.g., NTSR1 and P2RY2) which are among the 10 most highly expressed GPCRs overall in these cells, show very strong agonistinduced increases in intracellular calcium response and prominent functional response (migration), both of which appear to saturate at high levels of GPCR expression. We are not aware of prior such data for Gq/G11-coupled GPCRs, in particular in native cells.
Other results that imply a concordance between mRNA expression and functional response of prostanoid receptors in fibroblasts 23 and adrenoceptors in IPS-derived cardiomyocytes 24 support this observation in other GPCR systems. Thus, encouraging initial data (including those shown here) suggest that GPCR expression data can provide a useful first step in drug/target discovery efforts, with highly expressed GPCRs (or differentially expressed GPCRs in disease) likely to be the favored candidates for subsequent validation. Further studies are needed to determine the extent to which GPCR expression predicts intensity of downstream signaling events, such as protein phosphorylation, transcriptional regulation, etc. Affymetrix arrays are not recommended for such efforts, as they do not adequately distinguish between high-expressed and low-expressed GPCRs and, in addition, fail to detect many GPCRs.
Omics data such as those presented in this study reveal the high expression of numerous orphan GPCRs in human disease, for which such validation studies are more challenging. Given the apparent concordance between magnitude of expression and functional response of GPCRs, such data highlight specific highly expressed orphan GPCRs as priority candidates for further study and for attempts at deorphanization.
The data presented here highlight aspects of GPCR biology that merit further study. These include: a) what is the functional impact of alternative splicing of GPCRs? b) the high expression of many orphan GPCRs underscores the importance for further deorphanization efforts; the physiological role of much of the GPCRome remains unknown; c) given the abundance of GPCRs expressed in different cell types, do GPCRs that are more widely/ubiquitously expressed than others have a functional significance? d) which mechanisms regulate the expression of individual or groups of GPCRs in particular cell types? We anticipate that GPCRomic efforts, in combination with other techniques, will help address such issues, advance understanding of GPCR biology and aid in efforts to develop novel therapeutics. Recommended for focused study of GPCRs, especially for timesensitive data; easy data analysis Recommended for study of GPCRs but requires access to bioinformatics tools, plus may be timelag in generation of gene expression data Not recommended to assess GPCR expression * Costs shown are with academic pricing, these are subject to variation, depending on access to core facilities as well as institution type.
